Navigation Links
Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
Date:3/28/2008

o fast-scan cyclic voltammetry in anesthetized rats. A stimulation train was delivered to the ventral tegmental area every five minutes and the resultant dopamine and rate of reuptake were measured. Peak concentrations of dopamine and the rate of dopamine reuptake were monitored in response to intraperitoneal injections of MSI-1436, saline or nomafensine (a known inhibitor of DAT). Post-hoc analyses indicated that the peak dopamine concentration and the rate of dopamine reuptake (tau) significantly increased from baseline only after injection with nomifensine and that neither MSI-1436 nor the saline control had an effect on these measurements.

"These studies serve to further confirm the selectivity of MSI-1436 as an inhibitor of PTP-1B and addresses one of the critical issues involved in the development of anti-obesity drugs," states Jack Armstrong, President and Chief Executive Officer of Genaera. "The low addictive potential of MSI-1436 further differentiates it from many other drug candidates in development. While MSI- 1436 is being developed to treat both type 2 diabetes and obesity, we believe it is essential to demonstrate that the side effects seen in other weight-loss only drugs are not observed with MSI-1436. We continue to differentiate MSI- 1436 from other drugs for anti-obesity and anti-diabetes indications through our preclinical studies and look forward to reporting additional supportive clinical data later this year."

The researchers included Dr. Roitman and Seth A. Wescott from the University of Illinois at Chicago, as well as Michael P. McLane, Ph.D. and Henry R. Wolfe, Ph.D. from Genaera.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 tria
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 ... some of our Medicare resources and continue highlighting the success of the prescription drug ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... announces that a new market research report is ... Triple Analysis: Leukemia, Prostate Cancer and Apoptosis ... This triple analysis focuses on cancer drug development ... by the mechanism/target/effect of Apoptosis. Each of these ...
... SILVER SPRING, Md., May 3, 2011 The U.S. ... Commission (FTC) today announced a joint effort to remove ... treat, cure, and prevent sexually transmitted diseases (STDs). Among ... Viruxo, C-Cure, and Never An Outbreak. (Logo: ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 2Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 3Reportlinker Adds Triple Analysis: Leukemia, Prostate Cancer and Apoptosis 4FDA, FTC Act To Remove Fraudulent STD Products From The Market 2FDA, FTC Act To Remove Fraudulent STD Products From The Market 3
(Date:7/30/2015)... ... July 30, 2015 , ... The connection between a healthy head of hair and a feeling ... a full head of hair can have a devastating impact on the daily life of ... the work place, the consequences of hair loss are not to be taken lightly. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual intended to symbolize a ... Treatment Center have created an addiction graveyard. Sharing this with the public comes at ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he ...
(Date:7/30/2015)... ... , ... The American Telemedicine Association (ATA) is seeking presentations ... on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 attendees ... 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s most ...
(Date:7/30/2015)... ... 2015 , ... " DevExpress ” was featured on NewsWatch ... medium, and large businesses making an impact in their industry. Susan Bridges, a ... with viewers how DevExpress has provided software development tools that have helped app ...
(Date:7/30/2015)... (PRWEB) , ... July 30, ... ... released a video, “Beachside Nursing Center,” to announce its position as one ... ratings. Beachside's administrator and staff members support the CMS rating system, which ...
Breaking Medicine News(10 mins):Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2
... begun to help,United Healthcare Workers-West members fight unprecedented ... International Union President and,Secretary-Treasurer., "A Salute to ... Health Care Workers-West and their President, Sal Rosselli, ... at the Julia Morgan,Ballroom, Merchants Exchange Building, 465 ...
... Lasers Limited (ASX:,ELX), a global leader in the ... today announced the six-month clinical study results,for the ... annual meeting of the American Academy of Ophthalmology.,The ... FRCPath,FRCOphth (Hons), of St. Thomas, Hospital, London, under ...
... E, C did little to protect healthy men, either ... studies released Sunday cast doubt on the cardiac benefits ... Japanese researchers found that low-dose aspirin did not reduce ... 2 diabetes. , Second, Harvard researchers concluded that neither ...
... to foil a tumor from generating blood vessels to feed ... creating drugs aimed at stopping a key vessel growth-promoting protein. ... Researchers at the Moores Cancer Center at the University of ... that blocking that protein target, called VEGF, or vascular endothelial ...
... Room #283-285, Ernest N. Morial Convention Center) , A team ... five key proteins out of thousands secreted into blood draining ... certain quantities form the basis of a far more accurate ... attack in people with severely reduced blood flow, or ischemia. ...
... less likely than Caucasian patients to undergo coronary ... successful angioplasty, a type of percutaneous coronary intervention ... Hispanics also had a trend toward lower ... and bypass surgery, according to a study presented ...
Cached Medicine News:Health News:Health Care Workers Get Help Fighting Unprecedented Attacks from Service Employee International Union Leadership 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 2Health News:Ellex Announces Six-Month Results on Retina Regeneration Therapy 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Cancer drugs my build and not tear down blood vessels 2Health News:Cancer drugs my build and not tear down blood vessels 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 2Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 3Health News:Quintet of proteins forms new, early-warning blood test before heart attack strikes 4Health News:Hispanics less likely to have repeat revascularizations 1 year after angioplasty 2
... Immunoassay Control is a ... designed to complement the ... Immunoassay Plus Controls. This ... to include more complex ...
Liquichek Hematology-8 Control is a whole blood hematology control with extended stability for non-differential analyzers....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: